NO314695B1 - Peptider med veksthormonfrigjörende aktivitet, farmasöytiske sammensetninger inneholdende disse, fremgangsmåter for fremstilling oganvendelse - Google Patents

Peptider med veksthormonfrigjörende aktivitet, farmasöytiske sammensetninger inneholdende disse, fremgangsmåter for fremstilling oganvendelse Download PDF

Info

Publication number: NO314695B1
Authority: NO; Norway
Prior art keywords: ala; dphe; dala; nal; trp
Prior art date: 1991-08-22

Application number

NO19940592A

Other languages

English (en)

Norwegian (no)

Other versions

NO940592D0 (no

NO940592L (no

Inventor

Cyril Y Bowers

David Howard Coy

Original Assignee

Univ Tulane

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1991-08-22

Filing date

1994-02-21

Publication date

2003-05-05

1994-02-21 Application filed by Univ Tulane filed Critical Univ Tulane

1994-02-21 Publication of NO940592D0 publication Critical patent/NO940592D0/no

1994-04-14 Publication of NO940592L publication Critical patent/NO940592L/no

2003-05-05 Publication of NO314695B1 publication Critical patent/NO314695B1/no

Links

108090000765 processed proteins & peptides Proteins 0.000 title claims abstract description 119
239000000122 growth hormone Substances 0.000 title claims abstract description 77
102000018997 Growth Hormone Human genes 0.000 title claims abstract description 74
108010051696 Growth Hormone Proteins 0.000 title claims abstract description 74
102000004196 processed proteins & peptides Human genes 0.000 title claims abstract description 70
238000000034 method Methods 0.000 title claims description 31
238000002360 preparation method Methods 0.000 title claims description 8
239000008194 pharmaceutical composition Substances 0.000 title claims description 5
230000003578 releasing effect Effects 0.000 title description 16
241001465754 Metazoa Species 0.000 claims abstract description 25
150000001875 compounds Chemical class 0.000 claims description 65
150000003839 salts Chemical class 0.000 claims description 20
150000001413 amino acids Chemical class 0.000 claims description 18
125000000217 alkyl group Chemical group 0.000 claims description 15
COLNVLDHVKWLRT-MRVPVSSYSA-N D-phenylalanine Chemical compound OC(=O)[C@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-MRVPVSSYSA-N 0.000 claims description 11
125000000030 D-alanine group Chemical group [H]N([H])[C@](C([H])([H])[H])(C(=O)[*])[H] 0.000 claims description 10
125000004435 hydrogen atom Chemical group [H]* 0.000 claims description 10
238000004519 manufacturing process Methods 0.000 claims description 10
229910052739 hydrogen Inorganic materials 0.000 claims description 9
DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 claims description 8
102000007079 Peptide Fragments Human genes 0.000 claims description 7
108010033276 Peptide Fragments Proteins 0.000 claims description 7
125000003295 alanine group Chemical group N[C@@H](C)C(=O)* 0.000 claims description 7
230000001737 promoting effect Effects 0.000 claims description 7
KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 claims description 5
125000000174 L-prolyl group Chemical group [H]N1C([H])([H])C([H])([H])C([H])([H])[C@@]1([H])C(*)=O 0.000 claims description 5
-1 alkylamino carboxylic acid Chemical class 0.000 claims description 5
125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 claims description 5
KXDHJXZQYSOELW-UHFFFAOYSA-N Carbamic acid Chemical compound NC(O)=O KXDHJXZQYSOELW-UHFFFAOYSA-N 0.000 claims description 4
206010028980 Neoplasm Diseases 0.000 claims description 4
201000011510 cancer Diseases 0.000 claims description 4
206010006895 Cachexia Diseases 0.000 claims description 3
QIVBCDIJIAJPQS-SECBINFHSA-N D-tryptophane Chemical compound C1=CC=C2C(C[C@@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-SECBINFHSA-N 0.000 claims description 3
101710198286 Growth hormone-releasing hormone receptor Proteins 0.000 claims description 3
102100033365 Growth hormone-releasing hormone receptor Human genes 0.000 claims description 3
102000005157 Somatostatin Human genes 0.000 claims description 3
108010056088 Somatostatin Proteins 0.000 claims description 3
150000003862 amino acid derivatives Chemical class 0.000 claims description 3
238000006482 condensation reaction Methods 0.000 claims description 3
239000003085 diluting agent Substances 0.000 claims description 3
239000003814 drug Substances 0.000 claims description 3
230000000694 effects Effects 0.000 claims description 3
230000002265 prevention Effects 0.000 claims description 3
230000008569 process Effects 0.000 claims description 3
NHXLMOGPVYXJNR-ATOGVRKGSA-N somatostatin Chemical compound C([C@H]1C(=O)N[C@H](C(N[C@@H](CO)C(=O)N[C@@H](CSSC[C@@H](C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@@H](CC=2C3=CC=CC=C3NC=2)C(=O)N[C@@H](CCCCN)C(=O)N[C@H](C(=O)N1)[C@@H](C)O)NC(=O)CNC(=O)[C@H](C)N)C(O)=O)=O)[C@H](O)C)C1=CC=CC=C1 NHXLMOGPVYXJNR-ATOGVRKGSA-N 0.000 claims description 3
229960000553 somatostatin Drugs 0.000 claims description 3
239000000556 agonist Substances 0.000 claims description 2
239000003937 drug carrier Substances 0.000 claims description 2
WRHZVMBBRYBTKZ-UHFFFAOYSA-N pyrrole-2-carboxylic acid Chemical compound OC(=O)C1=CC=CN1 WRHZVMBBRYBTKZ-UHFFFAOYSA-N 0.000 claims description 2
238000010532 solid phase synthesis reaction Methods 0.000 claims description 2
239000000243 solution Substances 0.000 description 51
XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 50
OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 43
229920001184 polypeptide Polymers 0.000 description 42
ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 33
YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 30
238000006243 chemical reaction Methods 0.000 description 29
229920005989 resin Polymers 0.000 description 27
239000011347 resin Substances 0.000 description 27
229910001868 water Inorganic materials 0.000 description 27
WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 24
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 23
235000019439 ethyl acetate Nutrition 0.000 description 19
HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 18
238000007792 addition Methods 0.000 description 18
239000007787 solid Substances 0.000 description 18
210000004369 blood Anatomy 0.000 description 17
239000008280 blood Substances 0.000 description 17
229940024606 amino acid Drugs 0.000 description 16
235000001014 amino acid Nutrition 0.000 description 16
239000000203 mixture Substances 0.000 description 16
210000002966 serum Anatomy 0.000 description 15
241000282412 Homo Species 0.000 description 14
241000700159 Rattus Species 0.000 description 14
239000000047 product Substances 0.000 description 13
QOSSAOTZNIDXMA-UHFFFAOYSA-N Dicylcohexylcarbodiimide Chemical compound C1CCCCC1N=C=NC1CCCCC1 QOSSAOTZNIDXMA-UHFFFAOYSA-N 0.000 description 11
230000037396 body weight Effects 0.000 description 11
XKRFYHLGVUSROY-UHFFFAOYSA-N Argon Chemical compound [Ar] XKRFYHLGVUSROY-UHFFFAOYSA-N 0.000 description 10
238000004128 high performance liquid chromatography Methods 0.000 description 10
239000008346 aqueous phase Substances 0.000 description 9
239000000706 filtrate Substances 0.000 description 9
239000011541 reaction mixture Substances 0.000 description 9
102100033367 Appetite-regulating hormone Human genes 0.000 description 8
COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 description 8
239000003153 chemical reaction reagent Substances 0.000 description 8
125000006239 protecting group Chemical group 0.000 description 8
239000011734 sodium Substances 0.000 description 8
230000002195 synergetic effect Effects 0.000 description 8
NWQWNCILOXTTHF-HLCSKTDOSA-N (2s)-6-amino-2-[[(2r)-2-[[(2s)-2-[[(2s)-2-[[(2r)-2-[[(2s)-2-[[(2s)-2-aminopropanoyl]amino]-3-(1h-imidazol-5-yl)propanoyl]amino]-3-naphthalen-2-ylpropanoyl]amino]propanoyl]amino]-3-(1h-indol-3-yl)propanoyl]amino]-3-phenylpropanoyl]amino]hexanamide Chemical compound C([C@H](NC(=O)[C@@H](N)C)C(=O)N[C@H](CC=1C=C2C=CC=CC2=CC=1)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCCN)C(N)=O)C1=CNC=N1 NWQWNCILOXTTHF-HLCSKTDOSA-N 0.000 description 7
101710119601 Growth hormone-releasing peptides Proteins 0.000 description 7
VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 7
108010083553 alanyl-histidyl-(2-naphthyl)alanyl-tryptophyl-phenylalanyl-lysinamide Proteins 0.000 description 7
239000001257 hydrogen Substances 0.000 description 7
230000001965 increasing effect Effects 0.000 description 7
NTYJJOPFIAHURM-UHFFFAOYSA-N Histamine Chemical compound NCCC1=CN=CN1 NTYJJOPFIAHURM-UHFFFAOYSA-N 0.000 description 6
241000124008 Mammalia Species 0.000 description 6
CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 6
DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 6
238000005859 coupling reaction Methods 0.000 description 6
239000007789 gas Substances 0.000 description 6
238000001727 in vivo Methods 0.000 description 6
239000007924 injection Substances 0.000 description 6
238000002347 injection Methods 0.000 description 6
238000001556 precipitation Methods 0.000 description 6
238000003127 radioimmunoassay Methods 0.000 description 6
239000002904 solvent Substances 0.000 description 6
238000003828 vacuum filtration Methods 0.000 description 6
HRNLPPBUBKMZMT-SSSXJSFTSA-N (2s)-6-amino-2-[[(2s)-2-[[(2s)-2-[[(2s)-2-[[(2r)-2-[[(2r)-2-aminopropanoyl]amino]-3-naphthalen-2-ylpropanoyl]amino]propanoyl]amino]-3-(1h-indol-3-yl)propanoyl]amino]-3-phenylpropanoyl]amino]hexanamide Chemical compound C([C@H](NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](C)NC(=O)[C@@H](CC=1C=C2C=CC=CC2=CC=1)NC(=O)[C@H](N)C)C(=O)N[C@@H](CCCCN)C(N)=O)C1=CC=CC=C1 HRNLPPBUBKMZMT-SSSXJSFTSA-N 0.000 description 5
QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 5
UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 5
102100022831 Somatoliberin Human genes 0.000 description 5
229910052786 argon Inorganic materials 0.000 description 5
239000012298 atmosphere Substances 0.000 description 5
PFKFTWBEEFSNDU-UHFFFAOYSA-N carbonyldiimidazole Chemical compound C1=CN=CN1C(=O)N1C=CN=C1 PFKFTWBEEFSNDU-UHFFFAOYSA-N 0.000 description 5
230000008878 coupling Effects 0.000 description 5
238000010168 coupling process Methods 0.000 description 5
MGHPNCMVUAKAIE-UHFFFAOYSA-N diphenylmethanamine Chemical compound C=1C=CC=CC=1C(N)C1=CC=CC=C1 MGHPNCMVUAKAIE-UHFFFAOYSA-N 0.000 description 5
108010085742 growth hormone-releasing peptide-2 Proteins 0.000 description 5
239000010410 layer Substances 0.000 description 5
229960000208 pralmorelin Drugs 0.000 description 5
ADFXKUOMJKEIND-UHFFFAOYSA-N 1,3-dicyclohexylurea Chemical compound C1CCCCC1NC(=O)NC1CCCCC1 ADFXKUOMJKEIND-UHFFFAOYSA-N 0.000 description 4
KRHYYFGTRYWZRS-UHFFFAOYSA-N Fluorane Chemical compound F KRHYYFGTRYWZRS-UHFFFAOYSA-N 0.000 description 4
HKXLAGBDJVHRQG-YFKPBYRVSA-N L-lysinamide Chemical compound NCCCC[C@H](N)C(N)=O HKXLAGBDJVHRQG-YFKPBYRVSA-N 0.000 description 4
KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 4
KDLHZDBZIXYQEI-UHFFFAOYSA-N Palladium Chemical compound [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 4
101710142969 Somatoliberin Proteins 0.000 description 4
239000002253 acid Substances 0.000 description 4
239000000674 adrenergic antagonist Substances 0.000 description 4
150000001412 amines Chemical class 0.000 description 4
125000000539 amino acid group Chemical group 0.000 description 4
239000012300 argon atmosphere Substances 0.000 description 4
210000004899 c-terminal region Anatomy 0.000 description 4
239000002552 dosage form Substances 0.000 description 4
238000001914 filtration Methods 0.000 description 4
239000000463 material Substances 0.000 description 4
229920006395 saturated elastomer Polymers 0.000 description 4
239000002002 slurry Substances 0.000 description 4
239000000126 substance Substances 0.000 description 4
230000001225 therapeutic effect Effects 0.000 description 4
VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 4
BDNKZNFMNDZQMI-UHFFFAOYSA-N 1,3-diisopropylcarbodiimide Chemical compound CC(C)N=C=NC(C)C BDNKZNFMNDZQMI-UHFFFAOYSA-N 0.000 description 3
QGZKDVFQNNGYKY-UHFFFAOYSA-O Ammonium Chemical class [NH4+] QGZKDVFQNNGYKY-UHFFFAOYSA-O 0.000 description 3
241000283690 Bos taurus Species 0.000 description 3
QMMFVYPAHWMCMS-UHFFFAOYSA-N Dimethyl sulfide Chemical compound CSC QMMFVYPAHWMCMS-UHFFFAOYSA-N 0.000 description 3
108010016626 Dipeptides Proteins 0.000 description 3
ODKSFYDXXFIFQN-BYPYZUCNSA-N L-arginine Chemical compound OC(=O)[C@@H](N)CCCN=C(N)N ODKSFYDXXFIFQN-BYPYZUCNSA-N 0.000 description 3
DCXYFEDJOCDNAF-REOHCLBHSA-N L-asparagine Chemical compound OC(=O)[C@@H](N)CC(N)=O DCXYFEDJOCDNAF-REOHCLBHSA-N 0.000 description 3
239000004472 Lysine Substances 0.000 description 3
SJRJJKPEHAURKC-UHFFFAOYSA-N N-Methylmorpholine Chemical compound CN1CCOCC1 SJRJJKPEHAURKC-UHFFFAOYSA-N 0.000 description 3
DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 3
FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 3
238000010521 absorption reaction Methods 0.000 description 3
210000000577 adipose tissue Anatomy 0.000 description 3
230000002411 adverse Effects 0.000 description 3
125000003275 alpha amino acid group Chemical group 0.000 description 3
150000008064 anhydrides Chemical class 0.000 description 3
230000015572 biosynthetic process Effects 0.000 description 3
125000004432 carbon atom Chemical group C* 0.000 description 3
239000003054 catalyst Substances 0.000 description 3
238000009833 condensation Methods 0.000 description 3
230000005494 condensation Effects 0.000 description 3
BGRWYRAHAFMIBJ-UHFFFAOYSA-N diisopropylcarbodiimide Natural products CC(C)NC(=O)NC(C)C BGRWYRAHAFMIBJ-UHFFFAOYSA-N 0.000 description 3
BTCSSZJGUNDROE-UHFFFAOYSA-N gamma-aminobutanoic acid Natural products NCCCC(O)=O BTCSSZJGUNDROE-UHFFFAOYSA-N 0.000 description 3
239000011521 glass Substances 0.000 description 3
229960001340 histamine Drugs 0.000 description 3
125000004029 hydroxymethyl group Chemical group [H]OC([H])([H])* 0.000 description 3
230000007935 neutral effect Effects 0.000 description 3
239000003921 oil Substances 0.000 description 3
235000019198 oils Nutrition 0.000 description 3
238000010647 peptide synthesis reaction Methods 0.000 description 3
239000012071 phase Substances 0.000 description 3
239000006187 pill Substances 0.000 description 3
239000003488 releasing hormone Substances 0.000 description 3
239000007790 solid phase Substances 0.000 description 3
238000006467 substitution reaction Methods 0.000 description 3
239000003826 tablet Substances 0.000 description 3
238000010792 warming Methods 0.000 description 3
MTCFGRXMJLQNBG-REOHCLBHSA-N (2S)-2-Amino-3-hydroxypropansäure Chemical compound OC[C@H](N)C(O)=O MTCFGRXMJLQNBG-REOHCLBHSA-N 0.000 description 2
AHYFYYVVAXRMKB-KRWDZBQOSA-N (2s)-3-(1h-indol-3-yl)-2-(phenylmethoxycarbonylamino)propanoic acid Chemical compound N([C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)O)C(=O)OCC1=CC=CC=C1 AHYFYYVVAXRMKB-KRWDZBQOSA-N 0.000 description 2
QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 2
IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 2
241000238424 Crustacea Species 0.000 description 2
QNAYBMKLOCPYGJ-UHFFFAOYSA-N D-alpha-Ala Natural products CC([NH3+])C([O-])=O QNAYBMKLOCPYGJ-UHFFFAOYSA-N 0.000 description 2
FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 2
BWGNESOTFCXPMA-UHFFFAOYSA-N Dihydrogen disulfide Chemical compound SS BWGNESOTFCXPMA-UHFFFAOYSA-N 0.000 description 2
LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
208000033962 Fontaine progeroid syndrome Diseases 0.000 description 2
VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 2
108010010803 Gelatin Proteins 0.000 description 2
239000004471 Glycine Substances 0.000 description 2
239000000095 Growth Hormone-Releasing Hormone Substances 0.000 description 2
102000002265 Human Growth Hormone Human genes 0.000 description 2
108010000521 Human Growth Hormone Proteins 0.000 description 2
239000000854 Human Growth Hormone Substances 0.000 description 2
XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 2
QNAYBMKLOCPYGJ-UWTATZPHSA-N L-Alanine Natural products C[C@@H](N)C(O)=O QNAYBMKLOCPYGJ-UWTATZPHSA-N 0.000 description 2
XUJNEKJLAYXESH-REOHCLBHSA-N L-Cysteine Chemical compound SC[C@H](N)C(O)=O XUJNEKJLAYXESH-REOHCLBHSA-N 0.000 description 2
WTDRDQBEARUVNC-UHFFFAOYSA-N L-Dopa Natural products OC(=O)C(N)CC1=CC=C(O)C(O)=C1 WTDRDQBEARUVNC-UHFFFAOYSA-N 0.000 description 2
AHLPHDHHMVZTML-BYPYZUCNSA-N L-Ornithine Chemical compound NCCC[C@H](N)C(O)=O AHLPHDHHMVZTML-BYPYZUCNSA-N 0.000 description 2
CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 2
WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 2
HNDVDQJCIGZPNO-YFKPBYRVSA-N L-histidine Chemical compound OC(=O)[C@@H](N)CC1=CN=CN1 HNDVDQJCIGZPNO-YFKPBYRVSA-N 0.000 description 2
125000001176 L-lysyl group Chemical group [H]N([H])[C@]([H])(C(=O)[*])C([H])([H])C([H])([H])C([H])([H])C(N([H])[H])([H])[H] 0.000 description 2
125000000393 L-methionino group Chemical group [H]OC(=O)[C@@]([H])(N([H])[*])C([H])([H])C(SC([H])([H])[H])([H])[H] 0.000 description 2
OBSIQMZKFXFYLV-QMMMGPOBSA-N L-phenylalanine amide Chemical compound NC(=O)[C@@H](N)CC1=CC=CC=C1 OBSIQMZKFXFYLV-QMMMGPOBSA-N 0.000 description 2
125000002435 L-phenylalanyl group Chemical group O=C([*])[C@](N([H])[H])([H])C([H])([H])C1=C([H])C([H])=C([H])C([H])=C1[H] 0.000 description 2
OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 2
JVTAAEKCZFNVCJ-UHFFFAOYSA-M Lactate Chemical compound CC(O)C([O-])=O JVTAAEKCZFNVCJ-UHFFFAOYSA-M 0.000 description 2
JGFZNNIVVJXRND-UHFFFAOYSA-N N,N-Diisopropylethylamine (DIPEA) Chemical compound CCN(C(C)C)C(C)C JGFZNNIVVJXRND-UHFFFAOYSA-N 0.000 description 2
NQTADLQHYWFPDB-UHFFFAOYSA-N N-Hydroxysuccinimide Chemical compound ON1C(=O)CCC1=O NQTADLQHYWFPDB-UHFFFAOYSA-N 0.000 description 2
MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 description 2
229910019142 PO4 Inorganic materials 0.000 description 2
VJLLEKDQJSMHRU-STQMWFEESA-N Phe-Gly-Met Chemical compound [H]N[C@@H](CC1=CC=CC=C1)C(=O)NCC(=O)N[C@@H](CCSC)C(O)=O VJLLEKDQJSMHRU-STQMWFEESA-N 0.000 description 2
108010007568 Protamines Chemical class 0.000 description 2
102000007327 Protamines Human genes 0.000 description 2
241000282887 Suidae Species 0.000 description 2
QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 2
241000473945 Theria <moth genus> Species 0.000 description 2
241000251539 Vertebrata <Metazoa> Species 0.000 description 2
239000012445 acidic reagent Substances 0.000 description 2
230000001154 acute effect Effects 0.000 description 2
239000002671 adjuvant Substances 0.000 description 2
229910052783 alkali metal Inorganic materials 0.000 description 2
150000001408 amides Chemical class 0.000 description 2
238000004458 analytical method Methods 0.000 description 2
RDOXTESZEPMUJZ-UHFFFAOYSA-N anisole Chemical compound COC1=CC=CC=C1 RDOXTESZEPMUJZ-UHFFFAOYSA-N 0.000 description 2
125000003118 aryl group Chemical group 0.000 description 2
WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 2
210000000988 bone and bone Anatomy 0.000 description 2
239000002775 capsule Substances 0.000 description 2
210000004027 cell Anatomy 0.000 description 2
239000003795 chemical substances by application Substances 0.000 description 2
125000004218 chloromethyl group Chemical group [H]C([H])(Cl)* 0.000 description 2
239000000544 cholinesterase inhibitor Substances 0.000 description 2
238000000576 coating method Methods 0.000 description 2
125000004122 cyclic group Chemical group 0.000 description 2
238000010908 decantation Methods 0.000 description 2
238000002716 delivery method Methods 0.000 description 2
150000004662 dithiols Chemical class 0.000 description 2
POULHZVOKOAJMA-UHFFFAOYSA-M dodecanoate Chemical compound CCCCCCCCCCCC([O-])=O POULHZVOKOAJMA-UHFFFAOYSA-M 0.000 description 2
229940079593 drug Drugs 0.000 description 2
238000010828 elution Methods 0.000 description 2
239000003995 emulsifying agent Substances 0.000 description 2
239000000839 emulsion Substances 0.000 description 2
238000009472 formulation Methods 0.000 description 2
239000012634 fragment Substances 0.000 description 2
239000012458 free base Substances 0.000 description 2
229960003692 gamma aminobutyric acid Drugs 0.000 description 2
238000002290 gas chromatography-mass spectrometry Methods 0.000 description 2
239000008273 gelatin Substances 0.000 description 2
229920000159 gelatin Polymers 0.000 description 2
235000019322 gelatine Nutrition 0.000 description 2
235000011852 gelatine desserts Nutrition 0.000 description 2
238000010438 heat treatment Methods 0.000 description 2
229910000040 hydrogen fluoride Inorganic materials 0.000 description 2
239000003701 inert diluent Substances 0.000 description 2
239000003112 inhibitor Substances 0.000 description 2
238000007912 intraperitoneal administration Methods 0.000 description 2
238000001990 intravenous administration Methods 0.000 description 2
229940070765 laurate Drugs 0.000 description 2
HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 2
238000001819 mass spectrum Methods 0.000 description 2
238000002844 melting Methods 0.000 description 2
230000008018 melting Effects 0.000 description 2
235000013336 milk Nutrition 0.000 description 2
239000008267 milk Substances 0.000 description 2
210000004080 milk Anatomy 0.000 description 2
210000003205 muscle Anatomy 0.000 description 2
125000005487 naphthalate group Chemical group 0.000 description 2
229910052757 nitrogen Inorganic materials 0.000 description 2
231100000252 nontoxic Toxicity 0.000 description 2
230000003000 nontoxic effect Effects 0.000 description 2
229940049964 oleate Drugs 0.000 description 2
ZQPPMHVWECSIRJ-KTKRTIGZSA-N oleic acid Chemical compound CCCCCCCC\C=C/CCCCCCCC(O)=O ZQPPMHVWECSIRJ-KTKRTIGZSA-N 0.000 description 2
239000012044 organic layer Substances 0.000 description 2
239000012074 organic phase Substances 0.000 description 2
229940039748 oxalate Drugs 0.000 description 2
238000007911 parenteral administration Methods 0.000 description 2
NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 2
239000010452 phosphate Substances 0.000 description 2
230000001817 pituitary effect Effects 0.000 description 2
239000002244 precipitate Substances 0.000 description 2
229940048914 protamine Drugs 0.000 description 2
230000022558 protein metabolic process Effects 0.000 description 2
230000002285 radioactive effect Effects 0.000 description 2
230000009467 reduction Effects 0.000 description 2
230000004044 response Effects 0.000 description 2
FSYKKLYZXJSNPZ-UHFFFAOYSA-N sarcosine Chemical group C[NH2+]CC([O-])=O FSYKKLYZXJSNPZ-UHFFFAOYSA-N 0.000 description 2
229910000029 sodium carbonate Inorganic materials 0.000 description 2
235000017550 sodium carbonate Nutrition 0.000 description 2
239000007909 solid dosage form Substances 0.000 description 2
241000894007 species Species 0.000 description 2
239000007858 starting material Substances 0.000 description 2
238000007920 subcutaneous administration Methods 0.000 description 2
KDYFGRWQOYBRFD-UHFFFAOYSA-L succinate(2-) Chemical compound [O-]C(=O)CCC([O-])=O KDYFGRWQOYBRFD-UHFFFAOYSA-L 0.000 description 2
239000000725 suspension Substances 0.000 description 2
229940095064 tartrate Drugs 0.000 description 2
238000012360 testing method Methods 0.000 description 2
YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 2
WROMPOXWARCANT-UHFFFAOYSA-N tfa trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F.OC(=O)C(F)(F)F WROMPOXWARCANT-UHFFFAOYSA-N 0.000 description 2
JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 2
229940070710 valerate Drugs 0.000 description 2
NQPDZGIKBAWPEJ-UHFFFAOYSA-N valeric acid Chemical compound CCCCC(O)=O NQPDZGIKBAWPEJ-UHFFFAOYSA-N 0.000 description 2
239000000080 wetting agent Substances 0.000 description 2
OGNSCSPNOLGXSM-UHFFFAOYSA-N (+/-)-DABA Natural products NCCC(N)C(O)=O OGNSCSPNOLGXSM-UHFFFAOYSA-N 0.000 description 1
DFZVZEMNPGABKO-SSDOTTSWSA-N (2r)-2-amino-3-pyridin-3-ylpropanoic acid Chemical compound OC(=O)[C@H](N)CC1=CC=CN=C1 DFZVZEMNPGABKO-SSDOTTSWSA-N 0.000 description 1
RRONHWAVOYADJL-OAHLLOKOSA-N (2r)-3-phenyl-2-(phenylmethoxycarbonylamino)propanoic acid Chemical compound C([C@H](C(=O)O)NC(=O)OCC=1C=CC=CC=1)C1=CC=CC=C1 RRONHWAVOYADJL-OAHLLOKOSA-N 0.000 description 1
OCLLVJCYGMCLJG-ZDUSSCGKSA-N (2s)-2-azaniumyl-2-naphthalen-1-ylpropanoate Chemical compound C1=CC=C2C([C@](N)(C(O)=O)C)=CC=CC2=C1 OCLLVJCYGMCLJG-ZDUSSCGKSA-N 0.000 description 1
125000003088 (fluoren-9-ylmethoxy)carbonyl group Chemical group 0.000 description 1
BWKMGYQJPOAASG-UHFFFAOYSA-N 1,2,3,4-tetrahydroisoquinoline-3-carboxylic acid Chemical compound C1=CC=C2CNC(C(=O)O)CC2=C1 BWKMGYQJPOAASG-UHFFFAOYSA-N 0.000 description 1
VYMPLPIFKRHAAC-UHFFFAOYSA-N 1,2-ethanedithiol Chemical compound SCCS VYMPLPIFKRHAAC-UHFFFAOYSA-N 0.000 description 1
HBAHZZVIEFRTEY-UHFFFAOYSA-N 2-heptylcyclohex-2-en-1-one Chemical compound CCCCCCCC1=CCCCC1=O HBAHZZVIEFRTEY-UHFFFAOYSA-N 0.000 description 1
241000251468 Actinopterygii Species 0.000 description 1
206010001497 Agitation Diseases 0.000 description 1
GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
208000010392 Bone Fractures Diseases 0.000 description 1
BTBUEUYNUDRHOZ-UHFFFAOYSA-N Borate Chemical compound [O-]B([O-])[O-] BTBUEUYNUDRHOZ-UHFFFAOYSA-N 0.000 description 1
CPELXLSAUQHCOX-UHFFFAOYSA-M Bromide Chemical compound [Br-] CPELXLSAUQHCOX-UHFFFAOYSA-M 0.000 description 1
OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical class [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
241000283707 Capra Species 0.000 description 1
VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 1
CKLJMWTZIZZHCS-UHFFFAOYSA-N D-OH-Asp Natural products OC(=O)C(N)CC(O)=O CKLJMWTZIZZHCS-UHFFFAOYSA-N 0.000 description 1
150000008574 D-amino acids Chemical group 0.000 description 1
FHZPGIUBXYVUOY-VWGYHWLBSA-N Dermorphin Chemical compound C([C@H](N)C(=O)N[C@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)NCC(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CO)C(N)=O)C1=CC=C(O)C=C1 FHZPGIUBXYVUOY-VWGYHWLBSA-N 0.000 description 1
RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 1
206010013883 Dwarfism Diseases 0.000 description 1
LVGKNOAMLMIIKO-UHFFFAOYSA-N Elaidinsaeure-aethylester Natural products CCCCCCCCC=CCCCCCCCC(=O)OCC LVGKNOAMLMIIKO-UHFFFAOYSA-N 0.000 description 1
WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 1
108010010234 HDL Lipoproteins Proteins 0.000 description 1
102000015779 HDL Lipoproteins Human genes 0.000 description 1
CPELXLSAUQHCOX-UHFFFAOYSA-N Hydrogen bromide Chemical compound Br CPELXLSAUQHCOX-UHFFFAOYSA-N 0.000 description 1
DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical class C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
208000015580 Increased body weight Diseases 0.000 description 1
CKLJMWTZIZZHCS-UWTATZPHSA-N L-Aspartic acid Natural products OC(=O)[C@H](N)CC(O)=O CKLJMWTZIZZHCS-UWTATZPHSA-N 0.000 description 1
WTDRDQBEARUVNC-LURJTMIESA-N L-DOPA Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C(O)=C1 WTDRDQBEARUVNC-LURJTMIESA-N 0.000 description 1
QUOGESRFPZDMMT-UHFFFAOYSA-N L-Homoarginine Natural products OC(=O)C(N)CCCCNC(N)=N QUOGESRFPZDMMT-UHFFFAOYSA-N 0.000 description 1
235000019766 L-Lysine Nutrition 0.000 description 1
FFEARJCKVFRZRR-UHFFFAOYSA-N L-Methionine Natural products CSCCC(N)C(O)=O FFEARJCKVFRZRR-UHFFFAOYSA-N 0.000 description 1
ONIBWKKTOPOVIA-BYPYZUCNSA-N L-Proline Chemical compound OC(=O)[C@@H]1CCCN1 ONIBWKKTOPOVIA-BYPYZUCNSA-N 0.000 description 1
QIVBCDIJIAJPQS-VIFPVBQESA-N L-Tryptophan Natural products C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 description 1
QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 description 1
150000008575 L-amino acids Chemical class 0.000 description 1
235000014852 L-arginine Nutrition 0.000 description 1
229930064664 L-arginine Natural products 0.000 description 1
239000004201 L-cysteine Substances 0.000 description 1
235000013878 L-cysteine Nutrition 0.000 description 1
ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 1
229930182816 L-glutamine Natural products 0.000 description 1
QUOGESRFPZDMMT-YFKPBYRVSA-N L-homoarginine Chemical compound OC(=O)[C@@H](N)CCCCNC(N)=N QUOGESRFPZDMMT-YFKPBYRVSA-N 0.000 description 1
229930182844 L-isoleucine Natural products 0.000 description 1
125000002061 L-isoleucyl group Chemical group [H]N([H])[C@]([H])(C(=O)[*])[C@](C([H])([H])[H])([H])C(C([H])([H])[H])([H])[H] 0.000 description 1
229930195722 L-methionine Natural products 0.000 description 1
QEFRNWWLZKMPFJ-ZXPFJRLXSA-N L-methionine (R)-S-oxide Chemical compound C[S@@](=O)CC[C@H]([NH3+])C([O-])=O QEFRNWWLZKMPFJ-ZXPFJRLXSA-N 0.000 description 1
QEFRNWWLZKMPFJ-YGVKFDHGSA-N L-methionine S-oxide Chemical compound CS(=O)CC[C@H](N)C(O)=O QEFRNWWLZKMPFJ-YGVKFDHGSA-N 0.000 description 1
QEFRNWWLZKMPFJ-UHFFFAOYSA-N L-methionine sulphoxide Natural products CS(=O)CCC(N)C(O)=O QEFRNWWLZKMPFJ-UHFFFAOYSA-N 0.000 description 1
229930182821 L-proline Natural products 0.000 description 1
125000002842 L-seryl group Chemical group O=C([*])[C@](N([H])[H])([H])C([H])([H])O[H] 0.000 description 1
AYFVYJQAPQTCCC-GBXIJSLDSA-N L-threonine Natural products C[C@@H](O)[C@H](N)C(O)=O AYFVYJQAPQTCCC-GBXIJSLDSA-N 0.000 description 1
125000000769 L-threonyl group Chemical group [H]N([H])[C@]([H])(C(=O)[*])[C@](O[H])(C([H])([H])[H])[H] 0.000 description 1
125000000510 L-tryptophano group Chemical group [H]C1=C([H])C([H])=C2N([H])C([H])=C(C([H])([H])[C@@]([H])(C(O[H])=O)N([H])[*])C2=C1[H] 0.000 description 1
125000003798 L-tyrosyl group Chemical group [H]N([H])[C@]([H])(C(=O)[*])C([H])([H])C1=C([H])C([H])=C(O[H])C([H])=C1[H] 0.000 description 1
108010007622 LDL Lipoproteins Proteins 0.000 description 1
102000007330 LDL Lipoproteins Human genes 0.000 description 1
GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
WHXSMMKQMYFTQS-UHFFFAOYSA-N Lithium Chemical class [Li] WHXSMMKQMYFTQS-UHFFFAOYSA-N 0.000 description 1
206010024769 Local reaction Diseases 0.000 description 1
FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical class [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
229920001367 Merrifield resin Polymers 0.000 description 1
101100270435 Mus musculus Arhgef12 gene Proteins 0.000 description 1
AHLPHDHHMVZTML-UHFFFAOYSA-N Orn-delta-NH2 Natural products NCCCC(N)C(O)=O AHLPHDHHMVZTML-UHFFFAOYSA-N 0.000 description 1
241000283973 Oryctolagus cuniculus Species 0.000 description 1
208000001132 Osteoporosis Diseases 0.000 description 1
241001494479 Pecora Species 0.000 description 1
239000002202 Polyethylene glycol Substances 0.000 description 1
ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical class [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
101001075370 Rattus norvegicus Gamma-glutamyl hydrolase Proteins 0.000 description 1
101000633010 Rattus norvegicus Somatostatin Proteins 0.000 description 1
208000001647 Renal Insufficiency Diseases 0.000 description 1
108010077895 Sarcosine Proteins 0.000 description 1
208000020221 Short stature Diseases 0.000 description 1
229920002472 Starch Polymers 0.000 description 1
238000000692 Student's t-test Methods 0.000 description 1
229930006000 Sucrose Natural products 0.000 description 1
CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
239000004473 Threonine Substances 0.000 description 1
DTQVDTLACAAQTR-UHFFFAOYSA-M Trifluoroacetate Chemical compound [O-]C(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-M 0.000 description 1
HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 1
238000002835 absorbance Methods 0.000 description 1
229940022663 acetate Drugs 0.000 description 1
230000002378 acidificating effect Effects 0.000 description 1
230000009471 action Effects 0.000 description 1
230000003213 activating effect Effects 0.000 description 1
239000012190 activator Substances 0.000 description 1
239000004480 active ingredient Substances 0.000 description 1
239000000048 adrenergic agonist Substances 0.000 description 1
230000032683 aging Effects 0.000 description 1
238000013019 agitation Methods 0.000 description 1
229960003767 alanine Drugs 0.000 description 1
150000001340 alkali metals Chemical class 0.000 description 1
229910052784 alkaline earth metal Inorganic materials 0.000 description 1
150000001342 alkaline earth metals Chemical class 0.000 description 1
150000003973 alkyl amines Chemical class 0.000 description 1
150000001370 alpha-amino acid derivatives Chemical class 0.000 description 1
235000008206 alpha-amino acids Nutrition 0.000 description 1
229940124277 aminobutyric acid Drugs 0.000 description 1
229910021529 ammonia Inorganic materials 0.000 description 1
150000003863 ammonium salts Chemical class 0.000 description 1
230000001195 anabolic effect Effects 0.000 description 1
239000000427 antigen Substances 0.000 description 1
230000000890 antigenic effect Effects 0.000 description 1
102000036639 antigens Human genes 0.000 description 1
108091007433 antigens Proteins 0.000 description 1
239000008365 aqueous carrier Substances 0.000 description 1
239000007864 aqueous solution Substances 0.000 description 1
239000003125 aqueous solvent Substances 0.000 description 1
125000003710 aryl alkyl group Chemical group 0.000 description 1
229960001230 asparagine Drugs 0.000 description 1
229960005261 aspartic acid Drugs 0.000 description 1
238000003556 assay Methods 0.000 description 1
125000004429 atom Chemical group 0.000 description 1
RXQNHIDQIJXKTK-UHFFFAOYSA-N azane;pentanoic acid Chemical compound [NH4+].CCCCC([O-])=O RXQNHIDQIJXKTK-UHFFFAOYSA-N 0.000 description 1
229910052788 barium Inorganic materials 0.000 description 1
DSAJWYNOEDNPEQ-UHFFFAOYSA-N barium atom Chemical class [Ba] DSAJWYNOEDNPEQ-UHFFFAOYSA-N 0.000 description 1
230000009286 beneficial effect Effects 0.000 description 1
229940050390 benzoate Drugs 0.000 description 1
125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 description 1
239000000872 buffer Substances 0.000 description 1
239000006172 buffering agent Substances 0.000 description 1
229910052791 calcium Inorganic materials 0.000 description 1
239000011575 calcium Chemical class 0.000 description 1
125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 1
239000012159 carrier gas Substances 0.000 description 1
HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 1
230000001684 chronic effect Effects 0.000 description 1
238000003776 cleavage reaction Methods 0.000 description 1
230000007012 clinical effect Effects 0.000 description 1
239000011248 coating agent Substances 0.000 description 1
238000001816 cooling Methods 0.000 description 1
239000002285 corn oil Substances 0.000 description 1
235000005687 corn oil Nutrition 0.000 description 1
238000002425 crystallisation Methods 0.000 description 1
230000008025 crystallization Effects 0.000 description 1
ORQXBVXKBGUSBA-UHFFFAOYSA-N cyclohexyl D-alanine Natural products OC(=O)C(N)CC1CCCCC1 ORQXBVXKBGUSBA-UHFFFAOYSA-N 0.000 description 1
125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 1
230000007812 deficiency Effects 0.000 description 1
230000001419 dependent effect Effects 0.000 description 1
238000003795 desorption Methods 0.000 description 1
125000005265 dialkylamine group Chemical group 0.000 description 1
150000004985 diamines Chemical class 0.000 description 1
238000010790 dilution Methods 0.000 description 1
239000012895 dilution Substances 0.000 description 1
MHUWZNTUIIFHAS-CLFAGFIQSA-N dioleoyl phosphatidic acid Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OCC(COP(O)(O)=O)OC(=O)CCCCCCC\C=C/CCCCCCCC MHUWZNTUIIFHAS-CLFAGFIQSA-N 0.000 description 1
201000010099 disease Diseases 0.000 description 1
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
239000002270 dispersing agent Substances 0.000 description 1
230000001804 emulsifying effect Effects 0.000 description 1
230000002708 enhancing effect Effects 0.000 description 1
150000002148 esters Chemical class 0.000 description 1
LVGKNOAMLMIIKO-QXMHVHEDSA-N ethyl oleate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OCC LVGKNOAMLMIIKO-QXMHVHEDSA-N 0.000 description 1
229940093471 ethyl oleate Drugs 0.000 description 1
230000029142 excretion Effects 0.000 description 1
238000013100 final test Methods 0.000 description 1
235000003599 food sweetener Nutrition 0.000 description 1
239000003205 fragrance Substances 0.000 description 1
108010074605 gamma-Globulins Proteins 0.000 description 1
108010077689 gamma-aminobutyryl-2-methyltryptophyl-2-methyltryptophyl-2-methyltryptophyl-lysinamide Proteins 0.000 description 1
229960002989 glutamic acid Drugs 0.000 description 1
239000008187 granular material Substances 0.000 description 1
230000005484 gravity Effects 0.000 description 1
230000012010 growth Effects 0.000 description 1
IXCSERBJSXMMFS-UHFFFAOYSA-N hcl hcl Chemical compound Cl.Cl IXCSERBJSXMMFS-UHFFFAOYSA-N 0.000 description 1
230000035876 healing Effects 0.000 description 1
239000001307 helium Substances 0.000 description 1
229910052734 helium Inorganic materials 0.000 description 1
SWQJXJOGLNCZEY-UHFFFAOYSA-N helium atom Chemical compound [He] SWQJXJOGLNCZEY-UHFFFAOYSA-N 0.000 description 1
229960002885 histidine Drugs 0.000 description 1
239000012456 homogeneous solution Substances 0.000 description 1
239000005556 hormone Substances 0.000 description 1
229940088597 hormone Drugs 0.000 description 1
QAOWNCQODCNURD-UHFFFAOYSA-M hydrogensulfate Chemical compound OS([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-M 0.000 description 1
230000007062 hydrolysis Effects 0.000 description 1
238000006460 hydrolysis reaction Methods 0.000 description 1
230000002267 hypothalamic effect Effects 0.000 description 1
JBFYUZGYRGXSFL-UHFFFAOYSA-N imidazolide Chemical compound C1=C[N-]C=N1 JBFYUZGYRGXSFL-UHFFFAOYSA-N 0.000 description 1
230000006872 improvement Effects 0.000 description 1
238000010348 incorporation Methods 0.000 description 1
239000012442 inert solvent Substances 0.000 description 1
229910001867 inorganic solvent Inorganic materials 0.000 description 1
239000003049 inorganic solvent Substances 0.000 description 1
230000010354 integration Effects 0.000 description 1
238000007918 intramuscular administration Methods 0.000 description 1
229910052742 iron Inorganic materials 0.000 description 1
230000001678 irradiating effect Effects 0.000 description 1
229960000310 isoleucine Drugs 0.000 description 1
210000004731 jugular vein Anatomy 0.000 description 1
201000006370 kidney failure Diseases 0.000 description 1
230000002147 killing effect Effects 0.000 description 1
DWKPPFQULDPWHX-VKHMYHEASA-N l-alanyl ester Chemical compound COC(=O)[C@H](C)N DWKPPFQULDPWHX-VKHMYHEASA-N 0.000 description 1
BRHPBVXVOVMTIQ-ZLELNMGESA-N l-leucine l-leucine Chemical compound CC(C)C[C@H](N)C(O)=O.CC(C)C[C@H](N)C(O)=O BRHPBVXVOVMTIQ-ZLELNMGESA-N 0.000 description 1
229940001447 lactate Drugs 0.000 description 1
239000008101 lactose Substances 0.000 description 1
229960004502 levodopa Drugs 0.000 description 1
150000002632 lipids Chemical class 0.000 description 1
239000007788 liquid Substances 0.000 description 1
239000008297 liquid dosage form Substances 0.000 description 1
229910052744 lithium Inorganic materials 0.000 description 1
239000000314 lubricant Substances 0.000 description 1
235000018977 lysine Nutrition 0.000 description 1
229910052749 magnesium Inorganic materials 0.000 description 1
239000011777 magnesium Chemical class 0.000 description 1
235000019359 magnesium stearate Nutrition 0.000 description 1
230000014759 maintenance of location Effects 0.000 description 1
239000011159 matrix material Substances 0.000 description 1
230000004060 metabolic process Effects 0.000 description 1
229910052751 metal Inorganic materials 0.000 description 1
239000002184 metal Substances 0.000 description 1
229960004452 methionine Drugs 0.000 description 1
UZKWTJUDCOPSNM-UHFFFAOYSA-N methoxybenzene Substances CCCCOC=C UZKWTJUDCOPSNM-UHFFFAOYSA-N 0.000 description 1
ZZDPGZAZMFNUBC-BTQNPOSSSA-N methyl (2r)-2-amino-3-naphthalen-1-ylpropanoate;hydrochloride Chemical compound Cl.C1=CC=C2C(C[C@@H](N)C(=O)OC)=CC=CC2=C1 ZZDPGZAZMFNUBC-BTQNPOSSSA-N 0.000 description 1
150000007522 mineralic acids Chemical class 0.000 description 1
230000021332 multicellular organism growth Effects 0.000 description 1
238000006386 neutralization reaction Methods 0.000 description 1
FEMOMIGRRWSMCU-UHFFFAOYSA-N ninhydrin Chemical compound C1=CC=C2C(=O)C(O)(O)C(=O)C2=C1 FEMOMIGRRWSMCU-UHFFFAOYSA-N 0.000 description 1
QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 description 1
229910000069 nitrogen hydride Inorganic materials 0.000 description 1
239000012457 nonaqueous media Substances 0.000 description 1
238000000655 nuclear magnetic resonance spectrum Methods 0.000 description 1
239000012038 nucleophile Substances 0.000 description 1
239000004006 olive oil Substances 0.000 description 1
235000008390 olive oil Nutrition 0.000 description 1
230000003287 optical effect Effects 0.000 description 1
150000007524 organic acids Chemical class 0.000 description 1
150000002895 organic esters Chemical class 0.000 description 1
229960003104 ornithine Drugs 0.000 description 1
230000003647 oxidation Effects 0.000 description 1
238000007254 oxidation reaction Methods 0.000 description 1
125000005740 oxycarbonyl group Chemical group [*:1]OC([*:2])=O 0.000 description 1
238000012856 packing Methods 0.000 description 1
239000008188 pellet Substances 0.000 description 1
230000000737 periodic effect Effects 0.000 description 1
229960005190 phenylalanine Drugs 0.000 description 1
230000001766 physiological effect Effects 0.000 description 1
208000003068 pituitary dwarfism Diseases 0.000 description 1
229920001223 polyethylene glycol Polymers 0.000 description 1
229910052700 potassium Inorganic materials 0.000 description 1
239000011591 potassium Chemical class 0.000 description 1
244000144977 poultry Species 0.000 description 1
239000000843 powder Substances 0.000 description 1
239000003755 preservative agent Substances 0.000 description 1
150000003141 primary amines Chemical class 0.000 description 1
229960002429 proline Drugs 0.000 description 1
238000000746 purification Methods 0.000 description 1
108020003175 receptors Proteins 0.000 description 1
102000005962 receptors Human genes 0.000 description 1
238000001953 recrystallisation Methods 0.000 description 1
230000002829 reductive effect Effects 0.000 description 1
238000011160 research Methods 0.000 description 1
230000000717 retained effect Effects 0.000 description 1
229940043230 sarcosine Drugs 0.000 description 1
239000012047 saturated solution Substances 0.000 description 1
230000007017 scission Effects 0.000 description 1
150000003335 secondary amines Chemical class 0.000 description 1
229960001153 serine Drugs 0.000 description 1
210000003491 skin Anatomy 0.000 description 1
229910052708 sodium Inorganic materials 0.000 description 1
239000011780 sodium chloride Substances 0.000 description 1
JXKPEJDQGNYQSM-UHFFFAOYSA-M sodium propionate Chemical compound [Na+].CCC([O-])=O JXKPEJDQGNYQSM-UHFFFAOYSA-M 0.000 description 1
239000004324 sodium propionate Substances 0.000 description 1
229960003212 sodium propionate Drugs 0.000 description 1
235000010334 sodium propionate Nutrition 0.000 description 1
238000001228 spectrum Methods 0.000 description 1
238000013223 sprague-dawley female rat Methods 0.000 description 1
NHXLMOGPVYXJNR-UHFFFAOYSA-N srif Chemical compound N1C(=O)C(C(C)O)NC(=O)C(CCCCN)NC(=O)C(CC=2C3=CC=CC=C3NC=2)NC(=O)C(CC=2C=CC=CC=2)NC(=O)C(CC=2C=CC=CC=2)NC(=O)C(CC(N)=O)NC(=O)C(CCCCN)NC(=O)C(NC(=O)CNC(=O)C(C)N)CSSCC(C(O)=O)NC(=O)C(CO)NC(=O)C(C(O)C)NC(=O)C1CC1=CC=CC=C1 NHXLMOGPVYXJNR-UHFFFAOYSA-N 0.000 description 1
239000008107 starch Substances 0.000 description 1
235000019698 starch Nutrition 0.000 description 1
239000008223 sterile water Substances 0.000 description 1
239000003206 sterilizing agent Substances 0.000 description 1
239000005720 sucrose Substances 0.000 description 1
229910021653 sulphate ion Inorganic materials 0.000 description 1
238000001356 surgical procedure Methods 0.000 description 1
239000000375 suspending agent Substances 0.000 description 1
239000003765 sweetening agent Substances 0.000 description 1
230000005737 synergistic response Effects 0.000 description 1
238000003786 synthesis reaction Methods 0.000 description 1
230000002194 synthesizing effect Effects 0.000 description 1
239000006188 syrup Substances 0.000 description 1
235000020357 syrup Nutrition 0.000 description 1
230000009885 systemic effect Effects 0.000 description 1
238000012353 t test Methods 0.000 description 1
125000005931 tert-butyloxycarbonyl group Chemical group [H]C([H])([H])C(OC(*)=O)(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
229960002898 threonine Drugs 0.000 description 1
238000005809 transesterification reaction Methods 0.000 description 1
229960004799 tryptophan Drugs 0.000 description 1
229960004441 tyrosine Drugs 0.000 description 1
235000015112 vegetable and seed oil Nutrition 0.000 description 1
239000008158 vegetable oil Substances 0.000 description 1
239000003981 vehicle Substances 0.000 description 1
238000005303 weighing Methods 0.000 description 1
210000002268 wool Anatomy 0.000 description 1
230000029663 wound healing Effects 0.000 description 1
239000011701 zinc Substances 0.000 description 1
229910052725 zinc Inorganic materials 0.000 description 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/575—Hormones
- C07K14/60—Growth hormone-releasing factor [GH-RF], i.e. somatoliberin
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/02—Drugs for disorders of the endocrine system of the hypothalamic hormones, e.g. TRH, GnRH, CRH, GRH, somatostatin
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/06—Drugs for disorders of the endocrine system of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH
- A61P5/08—Drugs for disorders of the endocrine system of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH for decreasing, blocking or antagonising the activity of the anterior pituitary hormones

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Organic Chemistry (AREA)
Endocrinology (AREA)
General Health & Medical Sciences (AREA)
Medicinal Chemistry (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Diabetes (AREA)
Pharmacology & Pharmacy (AREA)
Bioinformatics & Cheminformatics (AREA)
Animal Behavior & Ethology (AREA)
Engineering & Computer Science (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Biophysics (AREA)
Toxicology (AREA)
Zoology (AREA)
Gastroenterology & Hepatology (AREA)
Biochemistry (AREA)
Genetics & Genomics (AREA)
Molecular Biology (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Obesity (AREA)
Hematology (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Peptides Or Proteins (AREA)

NO19940592A 1991-08-22 1994-02-21 Peptider med veksthormonfrigjörende aktivitet, farmasöytiske sammensetninger inneholdende disse, fremgangsmåter for fremstilling oganvendelse NO314695B1 (no)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US07/748,350 US5663146A (en)	1991-08-22	1991-08-22	Polypeptide analogues having growth hormone releasing activity
PCT/US1992/007026 WO1993004081A1 (en)	1991-08-22	1992-08-20	Peptides having growth hormone releasing activity

Publications (3)

Publication Number	Publication Date
NO940592D0 NO940592D0 (no)	1994-02-21
NO940592L NO940592L (no)	1994-04-14
NO314695B1 true NO314695B1 (no)	2003-05-05

Family

ID=25009088

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
NO19940592A NO314695B1 (no)	1991-08-22	1994-02-21	Peptider med veksthormonfrigjörende aktivitet, farmasöytiske sammensetninger inneholdende disse, fremgangsmåter for fremstilling oganvendelse

Country Status (26)

Country	Link
US (2)	US5663146A (bg)
EP (1)	EP0605484B1 (bg)
JP (1)	JP3179489B2 (bg)
KR (1)	KR100247212B1 (bg)
CN (1)	CN1035256C (bg)
AT (1)	ATE172742T1 (bg)
AU (1)	AU666673B2 (bg)
BG (1)	BG62655B1 (bg)
BR (2)	BR9206398A (bg)
CA (1)	CA2116120C (bg)
CZ (1)	CZ293281B6 (bg)
DE (1)	DE69227462T2 (bg)
DK (1)	DK0605484T3 (bg)
ES (1)	ES2124263T3 (bg)
FI (2)	FI120095B (bg)
HU (1)	HU223664B1 (bg)
IL (1)	IL102848A (bg)
MX (1)	MX9204861A (bg)
NO (1)	NO314695B1 (bg)
NZ (1)	NZ244034A (bg)
PL (1)	PL169562B1 (bg)
RO (1)	RO112507B1 (bg)
RU (1)	RU2126014C1 (bg)
SK (1)	SK282895B6 (bg)
WO (1)	WO1993004081A1 (bg)
ZA (1)	ZA926337B (bg)

Families Citing this family (108)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
AU6909194A (en)	1993-05-14	1994-12-12	Board Of Regents, The University Of Texas System	Preparation of n-cyanodithioimino-carbonates and 3-mercapto-5-amino-1h-1,2,4-triazole
WO1995017423A1 (en) *	1993-12-23	1995-06-29	Novo Nordisk A/S	Compounds with growth hormone releasing properties
AU683121B2 (en) *	1993-12-23	1997-10-30	Novo Nordisk A/S	Compounds with growth hormone releasing properties
US5798337A (en) *	1994-11-16	1998-08-25	Genentech, Inc.	Low molecular weight peptidomimetic growth hormone secretagogues
US20020111461A1 (en) *	1999-05-21	2002-08-15	Todd C. Somers	Low molecular weight peptidomimetic growth hormone secretagogues
AU711104B2 (en) *	1995-06-22	1999-10-07	Novo Nordisk A/S	Compounds with growth hormone releasing properties
KR20000010626A (ko) *	1996-04-24	2000-02-25	한센 핀 베네드, 안네 제헤르	성장호르몬 방출성을 갖는 화합물
EP1005484A1 (en)	1997-06-20	2000-06-07	Novo Nordisk A/S	Compounds with growth hormone releasing properties
US6127341A (en) *	1997-06-20	2000-10-03	Novo Nordisk A/S	Compounds with growth hormone releasing properties
ZA987383B (en) *	1997-08-19	2000-02-17	Lilly Co Eli	Treatment of congestive heart failure with growth hormone secretagogues.
US6329342B1 (en)	1997-08-19	2001-12-11	Eli Lilly And Company	Treatment of congestive heart failure with growth hormone secretagogues
HUP0100777A3 (en)	1998-01-16	2001-12-28	Novo Nordisk As	Tripeptides with growth hormone releasing properties, pharmaceutical compositions comprising thereof and their use
WO1999039730A1 (en) *	1998-02-09	1999-08-12	Kaken Pharmaceutical Co., Ltd.	Oral preparations containing peptides promoting the secretion of growth hormone
US6919315B1 (en)	1998-06-30	2005-07-19	Novo Nordisk A/S	Compounds with growth hormone releasing properties
US6682908B1 (en)	1998-07-10	2004-01-27	Merck & Co., Inc.	Mouse growth hormone secretagogue receptor
WO2000002919A1 (en)	1998-07-13	2000-01-20	Merck & Co., Inc.	Growth hormone secretagogue related receptors and nucleic acids
US6645726B1 (en)	1998-08-10	2003-11-11	Merck & Co., Inc.	Canine growth hormone secretagogue receptor
JP2002525265A (ja) *	1998-08-14	2002-08-13	アドミニストレイターズオブザトゥレーンエジュケーショナルファウンド	成長ホルモン放出活性を有する化合物
US6639076B1 (en)	1998-08-18	2003-10-28	Eli Lilly And Company	Growth hormone secretagogues
US6696063B1 (en) *	1998-12-30	2004-02-24	Applied Research Systems Ars Holding N.V.	Treatment of HIV-associated dysmorphia/dysmetabolic syndrome (HADDS) with or without lipodystrophy
JP2002542151A (ja) *	1999-02-18	2002-12-10	科研製薬株式会社	成長ホルモン分泌促進物質としての新規なアミド誘導体
US7022677B1 (en)	1999-02-18	2006-04-04	Kaken Pharmaceutical Co., Ltd.	Amide derivatives as growth hormone secretagogues
US6828331B1 (en) *	1999-02-19	2004-12-07	Eli Lilly And Company	Growth hormone secretagogues
MY133346A (en) *	1999-03-01	2007-11-30	Biogen Inc	Kit for radiolabeling ligands with yttrium-90
CN1367792A (zh) *	1999-06-25	2002-09-04	研究及应用科学协会股份有限公司	促生长素抑制素激动剂
ES2401939T3 (es) *	1999-07-23	2013-04-25	Kenji Kangawa	Nuevos péptidos
US20040192593A1 (en) *	1999-07-26	2004-09-30	Baylor College Of Medicine	Protease resistant ti-growth hormone releasing hormone
AU772752B2 (en)	1999-07-26	2004-05-06	Baylor College Of Medicine	Super-active porcine growth hormone releasing hormone analog
JP4691298B2 (ja) *	1999-10-12	2011-06-01	科研製薬株式会社	粉末吸入用製剤及びその製造方法
UA73530C2 (uk)	1999-11-10	2005-08-15	Ново Нордіск А/С	Сполука з властивостями вивільнювати гормон росту
JP3498041B2 (ja) *	2000-05-29	2004-02-16	科研製薬株式会社	プラルモレリン含有点鼻用製剤
DE60140285D1 (de)	2000-05-31	2009-12-10	Pfizer Prod Inc	Verwendung von Wachstumshormonsekretagoga zur Förderung der Beweglichkeit des Verdauungstrakts
US7622503B2 (en)	2000-08-24	2009-11-24	University Of Tennessee Research Foundation	Selective androgen receptor modulators and methods of use thereof
US7645898B2 (en)	2000-08-24	2010-01-12	University Of Tennessee Research Foundation	Selective androgen receptor modulators and method of use thereof
US7919647B2 (en)	2000-08-24	2011-04-05	University Of Tennessee Research Foundation	Selective androgen receptor modulators and methods of use thereof
US7855229B2 (en)	2000-08-24	2010-12-21	University Of Tennessee Research Foundation	Treating wasting disorders with selective androgen receptor modulators
BR0206919A (pt)	2001-02-02	2004-07-06	Conjuchem Inc	Derivados de fator de liberação de hormÈnio de crescimento de longa duração
US7125840B2 (en) *	2001-10-09	2006-10-24	Eli Lilly And Company	Substituted dipeptides as growth hormone secretagogues
AR037038A1 (es)	2001-10-26	2004-10-20	Baylor College Medicine	Una composicion y metodo para alterar la masa corporal magra y las propiedades oseas en un sujeto
US8853266B2 (en)	2001-12-06	2014-10-07	University Of Tennessee Research Foundation	Selective androgen receptor modulators for treating diabetes
US6831102B2 (en)	2001-12-07	2004-12-14	Bristol-Myers Squibb Company	Phenyl naphthol ligands for thyroid hormone receptor
AU2002357143B2 (en)	2001-12-11	2009-07-30	Advisys, Inc.	Growth hormone releasing hormone supplementation for treating chronically ill subjects
US7015219B2 (en)	2001-12-19	2006-03-21	Bristol-Myers Squibb Company	3-aryl-hydroxybenzoxazines and 3, 4-dihydro-3-aryl-hydroxybenzoxazines as selective estrogen receptor beta modulators
US7250405B2 (en) *	2002-02-07	2007-07-31	Baylor College Of Medicine	Modified pituitary gland development in offspring from expectant mother animals treated with growth hormone releasing hormone therapy
US7772433B2 (en)	2002-02-28	2010-08-10	University Of Tennessee Research Foundation	SARMS and method of use thereof
US7381730B2 (en)	2002-03-15	2008-06-03	Bristol-Myers Squibb Company	3-arylquinazoline derivatives as selective estrogen receptor beta modulators
US20060167268A1 (en) *	2002-04-09	2006-07-27	Eli Lilly And Company, Patent Division,	Growth hormone secretagogues
US7396846B2 (en) *	2002-04-09	2008-07-08	Eli Lilly And Company	Growth hormone secretagogues
WO2003094845A2 (en)	2002-05-08	2003-11-20	Bristol-Myers Squibb Company	Pyridine-based thyroid receptor ligands
US7405234B2 (en)	2002-05-17	2008-07-29	Bristol-Myers Squibb Company	Bicyclic modulators of androgen receptor function
WO2004017986A1 (en)	2002-08-23	2004-03-04	Valorisation-Recherche, Societe En Commandite	Growth hormone-releasing peptides in the treatment of prevention of atherosclerosis and hypercholesterolemia
WO2004045518A2 (en)	2002-11-15	2004-06-03	Bristol-Myers Squibb Company	Open chain prolyl urea-related modulators of androgen receptor function
US8309603B2 (en)	2004-06-07	2012-11-13	University Of Tennessee Research Foundation	SARMs and method of use thereof
TW200504021A (en)	2003-01-24	2005-02-01	Bristol Myers Squibb Co	Substituted anilide ligands for the thyroid receptor
CA2513743C (en) *	2003-01-28	2013-06-25	Advisys, Inc.	Reducing culling in herd animals growth hormone releasing hormone (ghrh)
WO2004069793A2 (en)	2003-01-28	2004-08-19	Bristol-Myers Squibb Company	Novel 2-substituted cyclic amines as calcium sensing receptor modulators
US7205322B2 (en)	2003-02-12	2007-04-17	Bristol-Myers Squibb Company	Thiazolidine compounds as calcium sensing receptor modulators
US7557143B2 (en)	2003-04-18	2009-07-07	Bristol-Myers Squibb Company	Thyroid receptor ligands
TW200424214A (en) *	2003-04-21	2004-11-16	Advisys Inc	Plasmid mediated GHRH supplementation for renal failures
US7459460B2 (en)	2003-05-28	2008-12-02	Bristol-Myers Squibb Company	Trisubstituted heteroaromatic compounds as calcium sensing receptor modulators
US7265145B2 (en)	2003-05-28	2007-09-04	Bristol-Myers Squibb Company	Substituted piperidines and pyrrolidines as calcium sensing receptor modulators and method
US7476653B2 (en)	2003-06-18	2009-01-13	Tranzyme Pharma, Inc.	Macrocyclic modulators of the ghrelin receptor
CA2575926C (en) *	2003-08-04	2014-02-25	Advisys, Inc.	Canine specific growth hormone releasing hormone
US7399826B1 (en)	2003-10-02	2008-07-15	Ali Sadat M	Peptide for promoting healing of fractures
ATE467417T1 (de) *	2003-12-31	2010-05-15	VGX Pharmaceuticals LLC	Reduzierung von arthritis und lahmheit bei personen unter supllement von wachstumshormon freisetzendem hormon (ghrh)
WO2005073371A2 (en) *	2004-01-20	2005-08-11	Advisys, Inc.	Enhanced secretion/retention of growth hormone releasing hormone (ghrh) from muscle cells by species-specific signal peptide
US20050164952A1 (en) *	2004-01-23	2005-07-28	Vital Pharmaceuticals, Inc.	Delivery system for growth hormone releasing peptides
US7820702B2 (en)	2004-02-04	2010-10-26	Bristol-Myers Squibb Company	Sulfonylpyrrolidine modulators of androgen receptor function and method
US7378426B2 (en)	2004-03-01	2008-05-27	Bristol-Myers Squibb Company	Fused heterotricyclic compounds as inhibitors of 17β-hydroxysteroid dehydrogenase 3
US7696241B2 (en)	2004-03-04	2010-04-13	Bristol-Myers Squibb Company	Bicyclic compounds as modulators of androgen receptor function and method
US7625923B2 (en)	2004-03-04	2009-12-01	Bristol-Myers Squibb Company	Bicyclic modulators of androgen receptor function
US9884038B2 (en)	2004-06-07	2018-02-06	University Of Tennessee Research Foundation	Selective androgen receptor modulator and methods of use thereof
US9889110B2 (en)	2004-06-07	2018-02-13	University Of Tennessee Research Foundation	Selective androgen receptor modulator for treating hormone-related conditions
US20060025368A1 (en) *	2004-07-23	2006-02-02	Advisys, Inc.	Growth hormone releasing hormone enhances vaccination response
WO2006023608A2 (en)	2004-08-18	2006-03-02	Elixir Pharmaceuticals, Inc.	Growth-hormone secretagogues
WO2006116401A1 (en)	2005-04-28	2006-11-02	Bristol-Myers Squibb Company	C-5 substituted quinazolinone derivatives as selective estrogen receptor beta modulators
JP2009506119A (ja)	2005-08-31	2009-02-12	ユニバーシティオブテネシーリサーチファウンデーション	選択的アンドロゲン受容体モジュレーターを用いる腎疾患、熱傷、創傷および脊髄損傷の処置
CU23558A1 (es)	2006-02-28	2010-07-20	Ct Ingenieria Genetica Biotech	Compuestos análogos a los secretagogos peptidicos de la hormona de crecimiento
WO2008006019A2 (en) *	2006-07-06	2008-01-10	Advisys Inc.	Growth hormone releasing hormone treatment to decrease cholesterol levels
MX2009000385A (es)	2006-07-12	2009-04-06	Univ Tennessee Res Foundation	Acil-anilidas sustituidas y metodos de uso de las mismas.
PL2069352T3 (pl)	2006-08-02	2014-03-31	Cytokinetics Inc	Określone cząstki chemiczne, kompozycje i sposoby
US8299248B2 (en)	2006-08-02	2012-10-30	Cytokinetics, Incorporated	Certain 1H-imidazo[4,5-b]pyrazin-2(3H)-ones and 1H-imidazo[4,5-b]pyrazin-2-ols and methods for their use
US10010521B2 (en)	2006-08-24	2018-07-03	University Of Tennessee Research Foundation	SARMs and method of use thereof
ES2581765T3 (es)	2006-08-24	2016-09-07	University Of Tennessee Research Foundation	Acilanilidas sustituidas y métodos de uso de las mismas
US9730908B2 (en)	2006-08-24	2017-08-15	University Of Tennessee Research Foundation	SARMs and method of use thereof
US9844528B2 (en)	2006-08-24	2017-12-19	University Of Tennessee Research Foundation	SARMs and method of use thereof
CN101657436A (zh)	2007-02-09	2010-02-24	特兰齐姆制药公司	大环生长素释放肽受体调节剂及其使用方法
WO2008134828A2 (en)	2007-05-04	2008-11-13	Katholieke Universiteit Leuven	Tissue degeneration protection
US7968603B2 (en)	2007-09-11	2011-06-28	University Of Tennessee Research Foundation	Solid forms of selective androgen receptor modulators
US8003689B2 (en)	2008-06-20	2011-08-23	Gtx, Inc.	Metabolites of selective androgen receptor modulators and methods of use thereof
AR081626A1 (es)	2010-04-23	2012-10-10	Cytokinetics Inc	Compuestos amino-piridazinicos, composiciones farmaceuticas que los contienen y uso de los mismos para tratar trastornos musculares cardiacos y esqueleticos
US9133123B2 (en)	2010-04-23	2015-09-15	Cytokinetics, Inc.	Certain amino-pyridines and amino-triazines, compositions thereof, and methods for their use
AR081331A1 (es)	2010-04-23	2012-08-08	Cytokinetics Inc	Amino- pirimidinas composiciones de las mismas y metodos para el uso de los mismos
WO2013190520A2 (en)	2012-06-22	2013-12-27	The General Hospital Corporation	Gh-releasing agents in the treatment of vascular stenosis and associated conditions
US9969683B2 (en)	2012-07-13	2018-05-15	Gtx, Inc.	Method of treating estrogen receptor (ER)-positive breast cancers with selective androgen receptor modulator (SARMS)
US9744149B2 (en)	2012-07-13	2017-08-29	Gtx, Inc.	Method of treating androgen receptor (AR)-positive breast cancers with selective androgen receptor modulator (SARMs)
US10258596B2 (en)	2012-07-13	2019-04-16	Gtx, Inc.	Method of treating HER2-positive breast cancers with selective androgen receptor modulators (SARMS)
US10314807B2 (en)	2012-07-13	2019-06-11	Gtx, Inc.	Method of treating HER2-positive breast cancers with selective androgen receptor modulators (SARMS)
LT2872482T (lt)	2012-07-13	2020-12-28	Oncternal Therapeutics, Inc.	Krūties vėžių gydymo būdas selektyviu androgeno receptoriaus moduliatoriumi
US9622992B2 (en)	2012-07-13	2017-04-18	Gtx, Inc.	Method of treating androgen receptor (AR)-positive breast cancers with selective androgen receptor modulator (SARMs)
US10987334B2 (en)	2012-07-13	2021-04-27	University Of Tennessee Research Foundation	Method of treating ER mutant expressing breast cancers with selective androgen receptor modulators (SARMs)
CA2889499C (en)	2012-10-24	2019-09-10	Daiichi Sankyo Company, Limited	Growth hormone secretagogue receptor agonists for treating amyotrophic lateral sclerosis
ES2924479T3 (es)	2013-04-08	2022-10-07	Harvard College	Composiciones para rejuvenecer las células madre del músculo esquelético
US9119832B2 (en)	2014-02-05	2015-09-01	The Regents Of The University Of California	Methods of treating mild brain injury
ES2864079T3 (es)	2014-05-30	2021-10-13	Pfizer	Derivados de carbonitrilo como moduladores selectivos del receptor de andrógenos
WO2017075535A1 (en)	2015-10-28	2017-05-04	Oxeia Biopharmaceuticals, Inc.	Methods of treating neurodegenerative conditions
MA56396A (fr)	2019-06-27	2022-05-04	Cytokinetics Inc	Polymorphes de 1-(2-((((trans)-3-fluoro-1-(3-fluoropyridin-2-yl)cyclobutyl)méthyl)amino)pyrimidin-5-yl)-1h-pyrrole-3-carboxamide
WO2023275715A1 (en)	2021-06-30	2023-01-05	Pfizer Inc.	Metabolites of selective androgen receptor modulators

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US4228156A (en) *	1979-03-30	1980-10-14	Beckman Instruments, Inc.	Synthetic peptides having pituitary growth hormone releasing activity
CA1175810A (en) *	1979-03-30	1984-10-09	Frank A. Momany	Synthetic peptides having pituitary growth hormone releasing activity
US4223021A (en) *	1979-03-30	1980-09-16	Beckman Instruments, Inc.	Synthetic peptides having pituitary growth hormone releasing activity
US4228157A (en) *	1979-03-30	1980-10-14	Beckman Instruments, Inc.	Synthetic peptides having pituitary growth hormone releasing activity
US4223019A (en) *	1979-03-30	1980-09-16	Beckman Instruments, Inc.	Synthetic peptides having pituitary growth hormone releasing activity
US4226857A (en) *	1979-03-30	1980-10-07	Beckman Instruments, Inc.	Synthetic peptides having pituitary growth hormone releasing activity
US4223020A (en) *	1979-03-30	1980-09-16	Beckman Instruments, Inc.	Synthetic peptides having pituitary growth hormone releasing activity
US4228155A (en) *	1979-03-30	1980-10-14	Beckman Instruments, Inc.	Synthetic peptides having pituitary growth hormone releasing activity
US4224316A (en) *	1979-03-30	1980-09-23	Beckman Instruments, Inc.	Synthetic peptides having pituitary growth hormone releasing activity
US4228158A (en) *	1979-03-30	1980-10-14	Beckman Instruments, Inc.	Synthetic peptides having pituitary growth hormone releasing activity
US4410512A (en) *	1981-12-28	1983-10-18	Beckman Instruments, Inc.	Combinations having synergistic pituitary growth hormone releasing activity
JPS58501861A (ja) *	1981-12-28	1983-11-04	ベツクマン・インストルメンツ・インコ−ポレ−テツド	下垂体成長ホルモン放出活性を有する合成ペプチド
US4410513A (en) *	1981-12-28	1983-10-18	Beckman Instruments, Inc.	Synthetic peptides having pituitary growth hormone releasing activity
GB8314646D0 (en) *	1983-05-26	1983-06-29	Wellcome Found	Pharmaceutical amides
US4880778A (en) *	1986-05-12	1989-11-14	Eastman Kodak Company	Combinations having synergistic growth hormone releasing activity and methods for use thereof
US4839344A (en) *	1987-06-12	1989-06-13	Eastman Kodak Company	Polypeptide compounds having growth hormone releasing activity
US4880777A (en) *	1987-09-01	1989-11-14	Eastman Kodak Company	Synthetic peptides having growth hormone releasing activity
AU637316B2 (en) *	1988-01-28	1993-05-27	Eastman Kodak Company	Polypeptide compounds having growth hormone releasing activity
AU628322B2 (en) *	1988-01-28	1992-09-17	Eastman Kodak Company	Polypeptide compounds having growth hormone releasing activity
DE68912775T2 (de) *	1988-05-11	1994-06-30	Polygen Holding Corp	Polypeptid-verbindungen mit hormonwachstumsbefreiender wirkung.
US5486505A (en) *	1990-07-24	1996-01-23	Polygen Holding Corporation	Polypeptide compounds having growth hormone releasing activity
WO1992001709A1 (en)	1990-07-24	1992-02-06	Eastman Kodak Company	Process for synthesizing peptides
IL98910A0 (en) *	1990-07-24	1992-07-15	Polygen Holding Corp	Polypeptide compounds having growth hormone releasing activity and pharmaceutical compositions containing them

1991
- 1991-08-22 US US07/748,350 patent/US5663146A/en not_active Expired - Lifetime
1992
- 1992-08-18 IL IL102848A patent/IL102848A/en not_active IP Right Cessation
- 1992-08-20 HU HU9400495A patent/HU223664B1/hu not_active IP Right Cessation
- 1992-08-20 WO PCT/US1992/007026 patent/WO1993004081A1/en not_active Ceased
- 1992-08-20 AU AU25416/92A patent/AU666673B2/en not_active Ceased
- 1992-08-20 ES ES92919262T patent/ES2124263T3/es not_active Expired - Lifetime
- 1992-08-20 JP JP50458593A patent/JP3179489B2/ja not_active Expired - Lifetime
- 1992-08-20 PL PL92302434A patent/PL169562B1/pl not_active IP Right Cessation
- 1992-08-20 RU RU94016393A patent/RU2126014C1/ru not_active IP Right Cessation
- 1992-08-20 NZ NZ244034A patent/NZ244034A/en not_active IP Right Cessation
- 1992-08-20 CZ CZ1994400A patent/CZ293281B6/cs not_active IP Right Cessation
- 1992-08-20 SK SK204-94A patent/SK282895B6/sk not_active IP Right Cessation
- 1992-08-20 DK DK92919262T patent/DK0605484T3/da active
- 1992-08-20 US US07/932,494 patent/US5776901A/en not_active Expired - Lifetime
- 1992-08-20 BR BR9206398A patent/BR9206398A/pt not_active Application Discontinuation
- 1992-08-20 DE DE69227462T patent/DE69227462T2/de not_active Expired - Lifetime
- 1992-08-20 RO RO94-00256A patent/RO112507B1/ro unknown
- 1992-08-20 AT AT92919262T patent/ATE172742T1/de active
- 1992-08-20 CA CA002116120A patent/CA2116120C/en not_active Expired - Lifetime
- 1992-08-20 KR KR1019940700542A patent/KR100247212B1/ko not_active Expired - Fee Related
- 1992-08-20 EP EP92919262A patent/EP0605484B1/en not_active Expired - Lifetime
- 1992-08-21 ZA ZA926337A patent/ZA926337B/xx unknown
- 1992-08-21 MX MX9204861A patent/MX9204861A/es unknown
- 1992-08-22 CN CN92110868A patent/CN1035256C/zh not_active Expired - Fee Related
1994
- 1994-02-18 BG BG98489A patent/BG62655B1/bg unknown
- 1994-02-21 NO NO19940592A patent/NO314695B1/no not_active IP Right Cessation
- 1994-02-21 FI FI940807A patent/FI120095B/fi not_active IP Right Cessation
1997
- 1997-04-22 BR BR1100309-0A patent/BR1100309A/pt active IP Right Grant
2005
- 2005-05-02 FI FI20050467A patent/FI120691B/fi not_active IP Right Cessation

Also Published As

Publication number	Publication date
CA2116120A1 (en)	1993-02-23
CN1073684A (zh)	1993-06-30
DE69227462T2 (de)	1999-04-08
NZ244034A (en)	1995-08-28
IL102848A (en)	1998-04-05
CA2116120C (en)	2002-12-03
KR100247212B1 (ko)	2000-03-15
NO940592D0 (no)	1994-02-21
DE69227462D1 (de)	1998-12-03
ZA926337B (en)	1993-04-22
HU223664B1 (hu)	2004-11-29
CZ40094A3 (en)	1994-11-16
PL169562B1 (pl)	1996-08-30
AU2541692A (en)	1993-03-16
IL102848A0 (en)	1993-01-31
SK20494A3 (en)	1994-10-05
FI120691B (fi)	2010-01-29
BR1100309A (pt)	2000-08-01
US5776901A (en)	1998-07-07
NO940592L (no)	1994-04-14
AU666673B2 (en)	1996-02-22
WO1993004081A1 (en)	1993-03-04
HU9400495D0 (en)	1994-05-30
HUT69178A (en)	1995-08-28
BG62655B1 (bg)	2000-04-28
EP0605484B1 (en)	1998-10-28
BR9206398A (pt)	1994-12-27
DK0605484T3 (da)	1999-07-05
ES2124263T3 (es)	1999-02-01
SK282895B6 (sk)	2003-01-09
JP3179489B2 (ja)	2001-06-25
CZ293281B6 (cs)	2004-03-17
RO112507B1 (ro)	1997-10-30
ATE172742T1 (de)	1998-11-15
US5663146A (en)	1997-09-02
EP0605484A1 (en)	1994-07-13
CN1035256C (zh)	1997-06-25
FI940807L (fi)	1994-02-21
JPH07507039A (ja)	1995-08-03
BG98489A (bg)	1995-02-28
RU2126014C1 (ru)	1999-02-10
FI120095B (fi)	2009-06-30
FI940807A0 (fi)	1994-02-21
MX9204861A (es)	1994-06-30
FI20050467L (fi)	2005-05-02

Legal Events

Date	Code	Title	Description
2012-03-26	MM1K	Lapsed by not paying the annual fees

Publication	Publication Date	Title
NO314695B1 (no)	2003-05-05	Peptider med veksthormonfrigjörende aktivitet, farmasöytiske sammensetninger inneholdende disse, fremgangsmåter for fremstilling oganvendelse
EP0398961B1 (en)	1994-11-02	Polypeptide compounds having growth hormone releasing activity
EP0400051B1 (en)	1995-05-10	Polypeptide compounds having growth hormone releasing activity
US5486505A (en)	1996-01-23	Polypeptide compounds having growth hormone releasing activity
EP0540676B1 (en)	1994-11-17	Peptide compounds having growth hormone releasing activity
EP0417165B1 (en)	1994-01-26	Polypeptide compounds having growth hormone releasing activity
US4880777A (en)	1989-11-14	Synthetic peptides having growth hormone releasing activity
WO2000009537A2 (en)	2000-02-24	Compounds having growth hormone releasing activity